Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
granted MK-5172/MK-8742 Breakthrough Therapy designation for treatment
of chronic hepatitis C virus infection. MK-5172/MK-8742 is an all-oral
combination regimen consisting of MK-5172, an investigational HCV NS3/4A
protease inhibitor, and MK-8742, an investigational HCV NS5A replication
complex inhibitor.
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestor Contacts:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more